# bib

id: cord-322748-a5131tv9
author: Yates, Mary K.
title: Flex-nucleoside analogues – Novel therapeutics against filoviruses
date: 2017-06-15
extension: .txt
mime: text/plain
words: 1496
sentence: 61
flesch: 47
cache: cache/cord-322748-a5131tv9.txt
txt: txt/cord-322748-a5131tv9.txt
summary:
  One therapeutic option for the development of antiviral treatments is the use of nucleoside analogues. Nucleoside analogues have long been the cornerstone of antiviral therapies due to their ability to inhibit viral replication because they mimic the structure of the natural nucleosides.


id: cord-267941-nrluar4e
author: Park, Eun-Mee
title: Production of Ebola virus-like particles in Drosophila melanogaster Schneider 2 cells
date: 2018-08-23
extension: .txt
mime: text/plain
words: 2164
sentence: 78
flesch: 44
cache: cache/cord-267941-nrluar4e.txt
txt: txt/cord-267941-nrluar4e.txt
summary:
  The formation of VLPs similar to Ebola virus particles was visualized in both EBOV Makonatransfected S2 cells and culture supernatant by transmission electron microscopy (TEM; Fig. 1B ). In vitro assembly into virus-like particles is an intrinsic quality of Pichia pastoris derived HCV core Hepatitis C virus structural proteins assemble into virus like particles in insect cells Outbreaks Chronology: Ebola Virus Disease Ebola: implications and perspectives Molecular mechanisms of Ebola virus pathogenesis: focus on cell death Differences in the post-translational modifications of human papillomavirus type 6b major capsid protein expressed from a baculovirus system Ebola haemorrhagic fever Assembly of human severe acute respiratory syndrome coronavirus-like particles Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles Analysis of Ebola virus and VLP release using an immunocapture assay Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development vaccine Hepatitis C virus-like particle induce virus-specific humoral and cellular immune response Synthesis of double-layered rotavirus-like particles using internal ribosome entry site vector system in stably-transformed Drosophila melanogaster Use of baculovirus expression system for generation of virus-like particles: success and challenges Safety and immunogenicity of a virus-like particle pandemic placebo-controlled trial of adults in Mexico Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structure A Kunjin replicon virus-like particle vaccine provides protection against Ebola virus infection in nonhuman primates Kunjin virus replicon-based vaccines expression Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg viruses Enhanced papillomavirus-like particle production in insect cells Different applications of virus-like particles in biology and medicine: vaccination and delivery systems Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infection Large-scale production and purification of VLP-based vaccines Advances in virus-like particle vaccine for filoviruses Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenges Ebola haemorrhagic fever in Zaire HIV-1 virus like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutrializing antibodies


id: cord-336986-rmxin1da
author: De Clercq, Erik
title: New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections
date: 2019-08-07
extension: .txt
mime: text/plain
words: 2730
sentence: 138
flesch: 50
cache: cache/cord-336986-rmxin1da.txt
txt: txt/cord-336986-rmxin1da.txt
summary:
  [3] In their final remarks, Sidwell et al. (1972) stated, rightfully that the antiviral spectrum of Virazole was the broadest ever reported for any syntheticm aterial that does not induce interferon, although the eventual clinicalu se of Virazole would eventually be limited to RNA virus infections. That T-705 (Favipiravir), as av iral RNA polymerase inhibitor, offers great potential in the treatment of aw idev ariety of RNA virus infections, has been reviewed repeatedly.


id: cord-352492-6ihyiwgb
author: Eickmann, Markus
date: 2018-05-06
extension: .txt
mime: text/plain
words: 3006
sentence: 107
flesch: 45
cache: cache/cord-352492-6ihyiwgb.txt
txt: txt/cord-352492-6ihyiwgb.txt
title:
  Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively

summary:
  In vivo studies Storage of platelets in additive solutions: effects of phosphate Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products The effectiveness of UVC pathogen inactivation system on reducing the Trypansosoma cruzi and Leishmania infantum burden in platelets The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets Challenge study of the pathogen reduction capacity of the THERAFLEX MB-Plasma technology The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma Emerging pathogens: the epidemiology and evolution of species jumps Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complementmediated virus neutralization Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients Clinical recognition and management of patients exposed to biological warfare agents At 0.15 J/cm 2 (75% of the full UVC dose), EBOV and MERS-CoV infectivity levels were below the detection limit, resulting in virus reduction factors of greater than 4.5 for EBOV and of greater than 3.7 for MERS-CoV. Table 2 , light doses as low as 30 J/cm 2 , or 25% of the standard full light dose of 120 J/cm 2 for LED-based illumination, inactivated EBOV and MERS-CoV in plasma to levels below the detection limit.


id: cord-017811-w38mbvdw
author: Volchkov, Viktor
title: Proteolytic Processing of Filovirus Glycoproteins
date: 2018-02-16
extension: .txt
mime: text/plain
words: 3531
sentence: 115
flesch: 42
cache: cache/cord-017811-w38mbvdw.txt
txt: txt/cord-017811-w38mbvdw.txt
summary:
  Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis Recognition sequences and structural elements contribute to shedding susceptibility of membrane proteins Host-primed Ebola virus GP exposes a hydrophobic NPC1 receptor-binding pocket, revealing a target for broadly neutralizing antibodies Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection Ectodomain shedding of the glycoprotein GP of Ebola virus Shedding of Ebola virus surface glycoprotein is a mechanism of self-regulation of cellular cytotoxicity and has a direct effect on virus infectivity The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding Shed GP of Ebola virus triggers immune activation and increased vascular permeability Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression Niemann-Pick C1 functions independently of Niemann-Pick C2 in the initial stage of retrograde transport of membrane-impermeable lysosomal cargo Structural basis for Marburg virus neutralization by a cross-reactive human antibody Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies Covalent modifications of the Ebola virus glycoprotein Proteolysis of the Ebola virus glycoproteins enhances virus binding and infectivity Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor Ebolavirus glycoprotein structure and mechanism of entry Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution Cathepsin B & L are not required for Ebola virus replication Filoviruses require endosomal cysteine proteases for entry but exhibit distinct protease preferences Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoproteindependent manner Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates Cellular entry of Ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing Biochemical analysis of the secreted and virion glycoproteins of Ebola virus Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein Direct visualization of Ebola virus fusion triggering in the endocytic pathway GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses Processing of the Ebola virus glycoprotein by the proprotein convertase furin Polymorphism of filovirus glycoproteins Recovery of infectious Ebola virus from complementary DNA:RNA editing of the GP gene and viral cytotoxicity Release of viral glycoproteins during Ebola virus infection Proteolytic processing of Marburg virus glycoprotein The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1 The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain Endoproteolytic processing of the Ebola virus envelope glycoprotein: cleavage is not required for function key: cord-017811-w38mbvdw authors: Volchkov, Viktor; Klenk, Hans Dieter title: Proteolytic Processing of Filovirus Glycoproteins date: 2018-02-16 journal: Activation of Viruses by Host Proteases DOI: 10.1007/978-3-319-75474-1_5 sha: doc_id: 17811 cord_uid: w38mbvdw Filoviruses (Marburg virus and Ebola virus) have a single envelope glycoprotein (GP) that initiates infection.


id: cord-318587-ewvnkdr2
author: Steeds, Kimberley
date: 2020-08-31
extension: .txt
mime: text/plain
words: 4989
sentence: 159
flesch: 35
cache: cache/cord-318587-ewvnkdr2.txt
txt: txt/cord-318587-ewvnkdr2.txt
title:
  Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies

summary:
  Pseudotyped virus neutralisation assay raw data were normalised as percentage (%) infection relative to mean values for pseudotyped virus only controls (equivalent to 100% infection), then IC 50 of pseudotyped virus neutralisation were estimated by model of nonlinear regression fit with settings for log (inhibitor) vs. normalised response curves using GraphPad Prism v5 (San Diego, California (CA), USA). A number of EBOV GP pseudotyped virus neutralisation assays have been developed to investigate immune responses to EBOV infection and vaccination [16] [17] [18] , as well as for evaluation of monoclonal antibody (mAb) therapies [19]


id: cord-350083-kldu8q8x
author: Oany, Arafat Rahman
date: 2015-08-08
extension: .txt
mime: text/plain
words: 5025
sentence: 196
flesch: 41
cache: cache/cord-350083-kldu8q8x.txt
txt: txt/cord-350083-kldu8q8x.txt
title:
  Highly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach

summary:
  Though at present, most of the vaccines are based on B cell immunity; vaccines based on T cell epitope have been encouraged recently. Thus, vaccination based on T cell epitope is a unique approach to obtain strong immune response against infectious agents, such as, viruses (Klein et al. 2005) .


id: cord-325423-d212h4bp
author: Carrion, Ricardo
title: A small nonhuman primate model for filovirus-induced disease
date: 2011-11-01
extension: .txt
mime: text/plain
words: 4933
sentence: 212
flesch: 36
cache: cache/cord-325423-d212h4bp.txt
txt: txt/cord-325423-d212h4bp.txt
summary:
  Involvement of fibroblastic reticular cells Ebola virus: from discovery to vaccine Evaluation in nonhuman primates of vaccines against Ebola virus Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2 Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus The ecology of Ebola virus Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure GB virus B infection of the common marmoset (Callithrix jacchus) and associated liver pathology Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates Marmoset models commonly used in biomedical research Plaque assay for Ebola virus Demand for nonhuman primate resources in the age of biodefense Ecologic and geographic distribution of filovirus disease Potential mammalian filovirus reservoirs Nasal and intrathalamic inoculations of primates with Tacaribe virus: protection against Argentine hemorrhagic fever and absence of neurovirulence Pyrosequencing as a method for SNP identification in the rhesus macaque (Macaca mulatta) Marburg agent disease: in monkeys Vervet monkey disease. Common marmosets (Callithrix jacchus) as a nonhuman primate model to assess the virulence of eastern equine encephalitis virus strains Attenuated Junin virus infection in Callithrix jacchus Protection of Junin virus-infected marmosets by passive administration of immune serum: association with late neurologic signs Disease modeling for Ebola and Marburg viruses A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever Development of a GB virus B marmoset model and its validation with a novel series of hepatitis C virus NS3 protease inhibitors Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity Pathogenesis of experimental Ebola virus infection in guinea pigs Pathology of experimental Ebola virus infection in African green monkeys.


id: cord-272576-ez731lif
author: Wada, Yoshiko
date: 2016-11-03
extension: .txt
mime: text/plain
words: 5673
sentence: 205
flesch: 43
cache: cache/cord-272576-ez731lif.txt
txt: txt/cord-272576-ez731lif.txt
title:
  Directional and reoccurring sequence change in zoonotic RNA virus genomes visualized by time-series word count

summary:
  A viruses reveals a mutational bias on the viral genomes Oligonucleotide motifs that disappear during the evolution of influenza in humans increase IFN-α secretion by plasmacytoid endritic cells Analysis of codon usage diversity of bacterial genes with a self-organizing map (SOM) -characterization of horizontally transferred genes with emphasis on the E. coli O157 genome Informatics for unveiling hidden genome signatures Prediction of directional changes of influenza A virus genome sequences with emphasis on pandemic H1N1/09 as a model case Novel bioinformatics strategies for prediction of directional sequence changes in influenza virus genomes and for surveillance of potentially hazardous strains Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Directional change in MERS virus genomes.


id: cord-003917-bswndfvk
author: Lalle, Eleonora
title: Pulmonary Involvement during the Ebola Virus Disease
date: 2019-08-24
extension: .txt
mime: text/plain
words: 5546
sentence: 181
flesch: 31
cache: cache/cord-003917-bswndfvk.txt
txt: txt/cord-003917-bswndfvk.txt
summary:
  A case report Antibody prevalence against haemorrhagic fever viruses in randomized representative Central African populations Risk factors for patients without a reported exposure CDC Centers for Disease Control and Prevention Guidance for Donning and Doffing Personal Protective Equipment (PPE) During Management of Patients with Ebola Virus Disease Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola Nucleic acid amplification-based diagnosis of respiratory virus infections Understanding Ebola virus transmission Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic The Repertoire of Adenovirus in Human Disease: The Innocuous to the Deadly Respiratory syncytial virus infection in adults Respiratory syncytial virus Measles virus: Cellular receptors, tropism and pathogenesis Pathological and ultrastructural analysis of surgical lung biopsies in patients with swine-origin influenza type A/H1N1 and acute respiratory failure Pathogenesis of severe acute respiratory syndrome Pathogenesis of the viral hemorrhagic fevers Dengue viruses can infect human primary lung epithelia as well as lung carcinoma cells, and can also induce the secretion of IL-6 and RANTES Pathogenesis of Lassa Fever. Soldier in the Fight against Respiratory Viruses Epithelial antimicrobial peptides and proteins: Their role in host defence and inflammation Centers for Disease Control and Prevention (CDC) CDC Grand Rounds: Discovering new diseases via enhanced partnership between public health and pathology experts Detection of Viral RNA in Tissues following Plasma Clearance from an Ebola Virus Infected Patient Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily Infection and activation of monocytes by Marburg and Ebola viruses Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease Human Ebola virus infection results in substantial immune activation Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014-2016 Outbreak in West Africa Into the Eye of the Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis Dendritic cells and the control of immunity The lack of maturation of Ebola virus-infected dendritic cells results from the cooperative effect of at least two viral domains Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation Immune barriers of Ebola virus infection Different features of Vδ2 T and NK cells in fatal and non-fatal human Ebola infections Ebola haemorrhagic fever virus:


id: cord-335093-tc1qo2k0
author: Gehring, Gerrit
title: The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry
date: 2014-08-01
extension: .txt
mime: text/plain
words: 5194
sentence: 189
flesch: 40
cache: cache/cord-335093-tc1qo2k0.txt
txt: txt/cord-335093-tc1qo2k0.txt
summary:
  Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology Engulfment of apoptotic cells by microvascular endothelial cells induces proinflammatory responses Isolation of primary human hepatocytes after partial hepatectomy: criteria for identification of the most promising liver specimen The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies Diverse CD81 proteins support hepatitis C virus infection Role of the transmembrane domain of Marburg virus surface protein GP in assembly of the viral envelope Impact of occludin intra-and inter-species variation on its co-receptor function for authentic hepatitis C virus particles Virus isolation and quantitation Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication Ion transport blockers inhibit human rhinovirus 2 release Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists Cellular electropharmacology of amiodarone Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever Ebola virus can be effectively neutralized by antibody produced in natural human infection Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype Amiodarone alters late endosomes and inhibits SARS coronavirus infection at a post-endosomal level Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses Cell entry by human pathogenic arenaviruses Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model pKa determination of verapamil by liquid-liquid partition Hantaan virus enters cells by clathrindependent receptor-mediated endocytosis Prolactin stimulates the L-type calcium channel-mediated transepithelial calcium transport in the duodenum of male rats Update on vascular endothelial Ca(2+) signalling: a tale of ion channels, pumps and transporters Calcium signaling siRNA screen for genes that affect Junin virus entry uncovers voltage-gated calcium channels as a therapeutic target We thank Hyeryun Choe, Francois-Loic Cosset, Jay Hooper, Stefan Kunz, Gary Nabel, Charles Rice and Anthony Sanchez for providing reagents and Sandra Westhaus for help with data analysis. We discovered that amiodarone, a multi-ion channel inhibitor and adrenoceptor antagonist, is a potent inhibitor of filovirus cell entry at concentrations that are routinely reached in human serum during anti-arrhythmic therapy.


id: cord-102206-mb0qcd0b
author: Seymour, Elif
title: Configurable Digital Virus Counter on Robust Universal DNA Chips
date: 2020-10-22
extension: .txt
mime: text/plain
words: 5918
sentence: 230
flesch: 48
cache: cache/cord-102206-mb0qcd0b.txt
txt: txt/cord-102206-mb0qcd0b.txt
summary:
  As we improved SP-IRIS to develop it as a robust POC diagnostic platform, we focused on optimizing virus capture efficiency of antibody microarray chips, one of the most important factors that affect assay sensitivity in solid-phase immunoassays. Antibody spots were ~150 μm in diameter.


id: cord-327641-hqnem2zs
author: Ji, Ying-Jie
title: Clinical presentations and outcomes of patients with Ebola virus disease in Freetown, Sierra Leone
date: 2016-11-03
extension: .txt
mime: text/plain
words: 5872
sentence: 256
flesch: 54
cache: cache/cord-327641-hqnem2zs.txt
txt: txt/cord-327641-hqnem2zs.txt
summary:
  Multivariate analyses showed that blood viral load (P = 0.005), confusion (P = 0.010), abdominal pain (P = 0.003), conjunctivitis (P = 0.035), and vomiting (P = 0.004) were factors independently associated with the outcomes of EVD patients. Factors such as high blood viral load, confusion, abdominal pain, vomiting and conjunctivitis were associated with poor prognosis for EVD patients.


id: cord-002463-qhtj1pef
author: Dash, Raju
title: In silico-based vaccine design against Ebola virus glycoprotein
date: 2017-03-21
extension: .txt
mime: text/plain
words: 5837
sentence: 240
flesch: 42
cache: cache/cord-002463-qhtj1pef.txt
txt: txt/cord-002463-qhtj1pef.txt
summary:
  Top scored eiptope subjected to 100 ns MD simulation **RMSF **RMSD **Hydrogen bond occupency analysis Secquence, having highest vaxijen score Prediction of B cell epitope, using-**T cell epitope prediction by proteasomal C terminal cleavage, TAP transport efficiency and MHC class 1 binding **Epitopes with IC50 value less than 50 for their binding to MHC class 1 molecule from IEDB analysis along with binding to highest number of alleles in both analyses were chosen **Epitope conservancy analysis **Population coverage analysis **Kolaskar and Tongaonkar antigenicity scale 48 **Emini surface accessibility prediction 47 **Karplus and Schulz flexibility prediction 49 **Bepipred linear epitope prediction 50 **Chou and Fasman beta turn prediction 52 Vaxijen analysis with a threshold score of >0. In silico prediction of B-and T-cell epitope on Lassa virus proteins for peptide based subunit vaccine design An in silico approach predicted potential therapeutics that can confer protection from maximum pathogenic Hantaviruses Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 A combined immuno-informatics and structure-based modeling approach for prediction of T cell epitopes of secretory proteins of Mycobacterium tuberculosis The Phyre2 web portal for protein modeling, prediction and analysis The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities Computations of Standard Binding Free Energies with Molecular Dynamics Simulations Highly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach Computational elucidation of potential antigenic CTL epitopes in Ebola virus Epitope-based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study A highly conserved GEQYQQLR epitope has been identified in the nucleoprotein of Ebola virus by using an in silico approach Conformational flexibility in designing peptides for immunology: the molecular dynamics approach Managing protein flexibility in docking and its applications Protein flexibility: Multiple molecular dynamics simulations of insulin chain B Toward an atomistic understanding of the immune synapse: Large-scale molecular dynamics simulation of a membrane-embedded TCR-pMHC-CD4 complex MHC-peptide binding is assisted by bound water molecules


id: cord-334560-1j9zmuub
author: Hunt, Catherine L.
title: Filovirus Entry: A Novelty in the Viral Fusion World
date: 2012-02-07
extension: .txt
mime: text/plain
words: 6453
sentence: 246
flesch: 43
cache: cache/cord-334560-1j9zmuub.txt
txt: txt/cord-334560-1j9zmuub.txt
summary:
  Sequence and residues critical for host cell binding Covalent modifications of the ebola virus glycoprotein Identification of the ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway Effect of flanking residues on the conformational sampling of the internal fusion peptide from ebola virus Functional importance of the coiled-coil of the ebola virus glycoprotein Involvement of viral envelope gp2 in ebola virus entry into cells expressing the macrophage galactose-type c-type lectin Permeabilization of the plasma membrane by ebola virus gp2 Distribution of hydrophobic residues is crucial for the fusogenic properties of the ebola virus gp2 fusion peptide Mutational analysis of the putative fusion domain of ebola virus glycoprotein Phosphatidylinositol-dependent membrane fusion induced by a putative fusogenic sequence of ebola virus Cell entry of enveloped viruses The role of the transmembrane and of the intraviral domain of glycoproteins in membrane fusion of enveloped viruses Ebola virus glycoprotein: Proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies The glycoproteins of marburg and ebola virus and their potential roles in pathogenesis Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions Pathogenesis of ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection Characterization of ebola virus entry by using pseudotyped viruses: Identification of receptor-deficient cell lines Distinct cellular interactions of secreted and transmembrane ebola virus glycoproteins A search for ebola virus in animals in the democratic republic of the Congo and Cameroon: Ecologic, virologic, and serologic surveys, 1979-1980. EBOV GP-mediated attachment and entry into early endosomes was unaffected in NPC1-defective cells; however, electron micrographs of NPC1 null cells infected with EBOV GP pseudotyped virus show the accumulation of perinuclear vesicles laden with EBOV GP pseudovirions that were positive for the lysosomal marker LAMP1


id: cord-297082-2rhoffx2
author: Yu, Changqing
date: 2020-09-15
extension: .txt
mime: text/plain
words: 6485
sentence: 301
flesch: 56
cache: cache/cord-297082-2rhoffx2.txt
txt: txt/cord-297082-2rhoffx2.txt
title:
  MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation

summary:
  After expression of GP and GPΔMLD with MARCH8 or furin, GP proteins were immunoprecipitated from supernatants and analyzed by WB. MARCH8 and GP expression was detected by WB using anti-HA or anti-FLAG.


id: cord-004069-nuep8nim
author: DeWald, Lisa Evans
title: In Vivo Activity of Amodiaquine against Ebola Virus Infection
date: 2019-12-27
extension: .txt
mime: text/plain
words: 5724
sentence: 218
flesch: 47
cache: cache/cord-004069-nuep8nim.txt
txt: txt/cord-004069-nuep8nim.txt
summary:
  Whereas AQ treatment did not lead to detectable beneficial effects on EVD progression in NHPs, there may be value in investigating novel AQ derivatives that have been improved for anti-EBOV potency and/or improved tolerability 22 . A possible impact from AQ side effects needs to be considered.


id: cord-003859-k8wfyj9b
author: Paweska, Janusz T.
date: 2019-07-24
extension: .txt
mime: text/plain
words: 6410
sentence: 226
flesch: 43
cache: cache/cord-003859-k8wfyj9b.txt
txt: txt/cord-003859-k8wfyj9b.txt
title:
  Evaluation of Diagnostic Performance of Three Indirect Enzyme-Linked Immunosorbent Assays for the Detection of IgG Antibodies to Ebola Virus in Human Sera

summary:
  Impact on outbreak response, case management and laboratory systems strengthening Lateral flow immunoassays for Ebola virus disease detection in Liberia Comparative performance of four rapid Ebola antigen-detection lateral flow immunoassays during the 2014-2016 Ebola epidemic in West Africa Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus Serological investigation of laboratory-confirmed and suspected Ebola virus disease patients during the late phase of the Ebola outbreak in Sierra Leone Production of antigens for ELISA Analysis of linear B-cell epitopes of the nucleoprotein of Ebola virus that distinguish Ebola virus subtypes Sequence analysis of the Ebola virus genome: Organization, genetic elements, and comparison with the genome of Marburg virus Enzyme-linked immunosorbent assays for detection of antibodies to Ebola and Marburg viruses using recombinant nucleoproteins Human survivors of disease outbreaks caused by Ebola or Marburg virus exhibit cross-reactive and long-lived antibody responses Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies Protective efficacy of neutralizing antibodies against Ebola virus infection Recombinant Ebola virus nucleoprotein and glycoprotein (Gabon 94 strain) provide new tools for the detection of human infections Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins Nucleoprotein-based indirect enzyme-linked immunosorbent assay (indirect ELISA) for detecting antibodies specific to Ebola virus and Marburg virus Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans Recombinant protein expression in Escherichia coli: Advances and challenges Engineering N-glycosylation pathways in the baculovirus-insect cell system Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: A cross-sectional study using a new non-invasive assay for antibodies to Ebola virus Standardization of the filovirus plaque assay for use in preclinical studies South African Ebola diagnostic response in Sierra Leone: A modular high biosafety field laboratory Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories World Health Organization. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections World Health Organization-Ebola virus Disease-Democratic Republic of the Congo DRC Ebola outbreak crisis update 11 313 unnecessary Ebola-related deaths:


id: cord-346267-l08ld2cy
author: Wertheim, Joel O.
title: Purifying Selection Can Obscure the Ancient Age of Viral Lineages
date: 2011-06-24
extension: .txt
mime: text/plain
words: 6416
sentence: 226
flesch: 38
cache: cache/cord-346267-l08ld2cy.txt
txt: txt/cord-346267-l08ld2cy.txt
summary:
  For each data set and substitution model, four independent BMCMC runs of 25 or 50 million generations were performed. In this study, we demonstrate the need to include relevant biological and evolutionary forces in substitution models.


id: cord-350565-mejd7blb
author: Lewnard, Joseph A
title: Emerging Challenges and Opportunities in Infectious Disease Epidemiology
date: 2019-03-16
extension: .txt
mime: text/plain
words: 6619
sentence: 159
flesch: 10
cache: cache/cord-350565-mejd7blb.txt
txt: txt/cord-350565-mejd7blb.txt
summary:
  The impact of past vaccination coverage and immunity on pertussis resurgence Direct and indirect effects in vaccine efficacy and effectiveness Population biology of infectious diseases: Part I Population biology of infectious diseases: Part II Modeling infectious disease dynamics in the complex landscape of global health BEAST 2: a software platform for Bayesian evolutionary analysis Supersize me: how whole-genome sequencing and big data are transforming epidemiology The surveillance of communicable diseases of national importance Completeness of notifiable infectious disease reporting in the United States: an analytical literature review US Centers for Disease Control and Prevention and its partners' contributions to global health security Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study US Agency for International Development Uncovering Earth's virome The Global Virome Project Pandemics: spend on surveillance, not prediction Global trends in emerging infectious diseases Towards a genomics-informed, realtime, global pathogen surveillance system Ebola virus disease: 11,323 deaths later, how far have we come? Simulation-guided design further presents the opportunity for applying adaptive trial methods (115) in the context of infectious disease outbreaks, where dynamic trends in incidence may highlight the benefits of such approaches.


id: cord-296399-vvbjulm9
author: Brinkmann, Constantin
date: 2017-12-07
extension: .txt
mime: text/plain
words: 7023
sentence: 268
flesch: 38
cache: cache/cord-296399-vvbjulm9.txt
txt: txt/cord-296399-vvbjulm9.txt
title:
  The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells

summary:
  These observations could indicate that VSV-G-mediated tetherin antagonism is not operative in VSV infected cells. Moreover, siRNAmediated knock-down of endogenous tetherin expression in HeLa cells reduced the amount of cell surface associated tetherin (Fig 3B) and increased viral titers roughly 10-fold as compared to cells transfected with scrambled siRNA or mock transfected cells (Fig 3C) .


id: cord-305653-f9vqn96o
author: Schmidt, Rebecca
title: Generation of therapeutic antisera for emerging viral infections
date: 2018-10-05
extension: .txt
mime: text/plain
words: 7926
sentence: 260
flesch: 36
cache: cache/cord-305653-f9vqn96o.txt
txt: txt/cord-305653-f9vqn96o.txt
summary:
  Blots were stained with a polyclonal goat antiserum against EBOV virus 72 at a working solution of 1:1000 or monoclonal antibodies against FLAG-tag, HA-tag, or c-myc-tag (all Sigma) at the recommended dilution to detect the respective epitopetagged NiV proteins. To put the titers obtained after immunization of rabbits in a clinically relevant context, total anti-EBOV antibodies were quantified in a validated whole-virion EBOV antibody capture enzyme-linked immunosorbent assay (ELISA), used to assess the antibody responses in survivors of EBOV virus disease during the West African outbreak, 37 as well as a virus neutralization assay (VNT) with EBOV Zaire strain Mayinga used to assess antibody responses in VSVΔG/EBOV-GP vaccinated volunteers using the same assay.


id: cord-337998-08tknscm
author: Sztuba-Solinska, Joanna
date: 2016-11-16
extension: .txt
mime: text/plain
words: 8292
sentence: 299
flesch: 42
cache: cache/cord-337998-08tknscm.txt
txt: txt/cord-337998-08tknscm.txt
title:
  A small stem-loop structure of the Ebola virus trailer is essential for replication and interacts with heat-shock protein A8

summary:
  The NCRs of RNA virus genomes have highly conserved primary and secondary structures (4) (5) (6) (7) . Reactivity to the SHAPE reagent 1M7 for EBOV minigenome RNA is shown in Figure 4A (Supplementary Figure S2) .


id: cord-256187-ofp7tupv
author: Kühl, A.
title: How Ebola Virus Counters the Interferon System
date: 2012-09-07
extension: .txt
mime: text/plain
words: 8613
sentence: 263
flesch: 36
cache: cache/cord-256187-ofp7tupv.txt
txt: txt/cord-256187-ofp7tupv.txt
summary:
  This ability of GP 1,2 is conserved between the GPs of the different EBOV species (Zaire, Sudan, Côte d'Ivoire and Reston), the proposed species BEBOV and the second filoviral genus MARV (Kaletsky et al., 2009; Lopez et al., 2010; Radoshitzky et al., 2010; Kühl et al., 2011a,b) . In contrast, no evidence for downregulation, relocalization away from the cell surface or degradation of tetherin was observed in the presence of EBOV-GP 1,2 or MARV-GP 1,2 (Kaletsky et al., 2009; Lopez et al., 2010; Radoshitzky et al., 2010; Kühl et al., 2011a) .


id: cord-330647-w1bpeqzg
author: Wong, Samson Sai-Yin
title: Ebola virus disease in nonendemic countries
date: 2015-05-31
extension: .txt
mime: text/plain
words: 8638
sentence: 333
flesch: 32
cache: cache/cord-330647-w1bpeqzg.txt
txt: txt/cord-330647-w1bpeqzg.txt
summary:
  Marburg hemorrhagic fever associated with multiple genetic lineages of virus Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection Multiple Ebola virus transmission events and rapid decline of central African wildlife A serological survey of Ebola virus infection in central African nonhuman primates Wild animal mortality monitoring and human Ebola outbreaks, Gabon and Republic of Congo Replication, pathogenicity, shedding, and transmission of Zaïre ebolavirus in pigs Review of Ebola virus infections in domestic animals Ebola virus antibody prevalence in dogs and human risk The natural history of Ebola virus in Africa Ebola and Marburg virus disease epidemics: preparedness, alert, control, and evaluation Ebola hemorrhagic fever transmission and risk factors of contacts Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread Transmission of Ebola hemorrhagic fever: a study of risk factors in family members Assessment of the risk of Ebola virus transmission from bodily fluids and fomites Emergence of Zaïre Ebola virus disease in Guinea Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain Transmission of Ebola virus from pigs to nonhuman primates Evaluation of transmission risks associated with in vivo replication of several high containment pathogens in a biosafety level 4 laboratory Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure World Health Organization. a compendium of 40 years of epidemiological, clinical, and laboratory studies ELISA for the detection of antibodies to Ebola viruses Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies Development of an immunofiltrationbased antigen-detection assay for rapid diagnosis of Ebola virus infection Enzyme immunosorbent assay for Ebola virus antigens in tissues of infected primates Rapid and simple detection of Ebola virus by reverse transcription-loop-mediated isothermal amplification Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method Comprehensive multiplex one-step real-time TaqMan qRT-PCR assays for detection and quantification of hemorrhagic fever viruses Simultaneous detection of CDC category A DNA and RNA bioterrorism agents by use of multiplex PCR & RT-PCR enzyme hybridization assays Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo Detection and molecular characterization of Ebola viruses causing disease in human and nonhuman primates Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan Clinical management of filovirus-infected patients Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients.


id: cord-003779-5yhoiv76
author: Singleton, Courtney D.
title: Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry
date: 2019-07-17
extension: .txt
mime: text/plain
words: 9005
sentence: 296
flesch: 39
cache: cache/cord-003779-5yhoiv76.txt
txt: txt/cord-003779-5yhoiv76.txt
summary:
  2017 update Vesicular stomatitis virus G protein acquires pH-independent fusion activity during transport in a polarized endometrial cell line Ebola virus and severe acute respiratory syndrome coronavirus display late cell entry kinetics: evidence that transport to NPC1ϩ endolysosomes is a rate-defining step pH-REMD simulations indicate that the catalytic aspartates of HIV-1 protease exist primarily in a monoprotonated state Basic local alignment search tool COBALT: constraint-based alignment tool for multiple protein sequences In silico prediction of Ebola Zaire GP1,2 immuno-dominant epitopes for the Balb/c mouse Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp cocktail using cryo-electron tomography and studies of cellular entry Pan-ebolavirus and panfilovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses Inhibition of Ebola virus entry by a C-peptide targeted to endosomes Inhibition of HIV entry by targeting the envelope transmembrane subunit gp41 Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein Identification of combinations of approved drugs with synergistic activity against Ebola virus in cell cultures PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data Automated docking with gridbased energy evaluation Using shape complementarity as an initial screen in designing ligands for a receptor binding site of known threedimensional structure Grid-based molecular footprint comparison method for docking and de novo design: application to HIVgp41 Implementation and evaluation of a docking-rescoring method using molecular footprint comparisons Comparison of multiple Amber force fields and development of improved protein backbone parameters Strategies for lead discovery: application of footprint similarity targeting HIVgp41 Docking validation resources: protein family and ligand flexibility experiments UCSF Chimera-a visualization system for exploratory research and analysis Fast, efficient generation of high-quality atomic charges. Explicit solvent particle mesh Ewald SPFP: speed without compromise-a mixed precision model for GPU accelerated molecular dynamics simulations VMD: visual molecular dynamics Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1 Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity The intracellular cargo receptor ERGIC-53 is required for the production of infectious arenavirus, coronavirus, and filovirus particles Optimization of lentiviral vector production using polyethylenimine-mediated transfection Transient mammalian cell transfection with polyethylenimine (PEI) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene Permanent inhibition of viral entry by covalent entrapment of HIV gp41 on the virus surface Clomiphene and its isomers block Ebola virus particle entry and infection with similar potency: potential therapeutic implications.


id: cord-355737-o0y4rn0z
author: Ng, Melinda
date: 2015-12-23
extension: .txt
mime: text/plain
words: 8969
sentence: 296
flesch: 40
cache: cache/cord-355737-o0y4rn0z.txt
txt: txt/cord-355737-o0y4rn0z.txt
title:
  Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats

summary:
  Rather, we used a diverse set of bat NPC1 sequences, only one of which is from African straw-colored fruit bats, to show that a number of codons, including residue 502, have evolved under recurrent positive selection. In this study, we uncover a pattern of virus and host species specificity in the filovirus susceptibility of bat cells, which can be explained by eLife digest Ebola virus and other filoviruses can cause devastating diseases in humans and other apes.


id: cord-102763-tc1z0nm9
author: Zhang, Yuan
title: IgY antibodies against Ebola virus possess post-exposure protection and excellent thermostability
date: 2020-05-21
extension: .txt
mime: text/plain
words: 1770
sentence: 54
flesch: 37
cache: cache/cord-102763-tc1z0nm9.txt
txt: txt/cord-102763-tc1z0nm9.txt
summary:
  Although several Ebola virus therapeutic antibodies have been reported in recent years, however, due to the poor thermal stability of mammalian antibody, their application in tropical endemic areas has been limited. The New England 452 journal of medicine New treatments for Ebola virus disease Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against 458 Antibody 461 therapeutics for Ebola virus disease.


id: cord-288734-xinkqs6u
author: Muñoz-Fontela, César
title: Ebola Virus Disease in Humans: Pathophysiology and Immunity
date: 2017-03-30
extension: .txt
mime: text/plain
words: 9966
sentence: 261
flesch: 27
cache: cache/cord-288734-xinkqs6u.txt
txt: txt/cord-288734-xinkqs6u.txt
summary:
  Perhaps one of the most surprising findings has been the low overall number of human cases presenting with bleeding (Schieffelin et al. 2014) , as well as the lack of correlation between bleeding and disease severity (Schieffelin et al. 2014; McElroy et al. 2014a, b) . Furthermore, in the Western African outbreak, hemorrhagic manifestations were rarely reported; fewer than 15% of all patients from Liberia and Sierra Leone had any bleeding symptom recorded (Chertow et al. 2014; Schieffelin et al. 2014; Lado et al. 2015; Yan et al. 2015; Dallatomasina et al. 2015; Li et al. 2016; Qin et al. 2015) , but two reports from a single center in Guinea reported bleeding in 51 and 26% of patients (Barry et al. 2014;


id: cord-284791-bgodmbru
author: Whitworth, Carrie
date: 2020-08-18
extension: .txt
mime: text/plain
words: 5177
sentence: 179
flesch: 47
cache: cache/cord-284791-bgodmbru.txt
txt: txt/cord-284791-bgodmbru.txt
title:
  Persistence of Bacteriophage Phi 6 on Porous and Nonporous Surfaces and the Potential for Its Use as an Ebola Virus or Coronavirus Surrogate

summary:
  World Health Organization Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study Assessment of the risk of Ebola virus transmission from bodily fluids and fomites Ebola virus RNA detection on fomites in close proximity to confirmed Ebola patients; N'Zerekore, Guinea Environmental contamination and persistence of Ebola virus RNA in an Ebola treatment center Evaluation of phi6 persistence and suitability as an enveloped virus surrogate The use of bacteriophages of the family Cystoviridae as surrogates for H5N1 highly pathogenic avian influenza viruses in persistence and inactivation studies The cystovirus phi6 as a simulant for Venezuelan equine encephalitis virus Survival of an enveloped virus on toys Evaluation of eluents for the recovery of an enveloped virus from hands by whole-hand sampling Survival of a surrogate virus on N95 respirator material Assessment of self-contamination during removal of personal protective equipment for Ebola patient care Virus transfer from personal protective equipment to healthcare employees' skin and clothing Ebola virus stability on surfaces and in fluids in simulated outbreak environments The survival of filoviruses in liquids, on solid substrates and in a dynamic aerosol Persistence of Ebola virus in sterilized wastewater Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces Survival of the enveloped virus Phi6 in droplets as a function of relative humidity, absolute humidity, and temperature Inactivation of avian influenza viruses on porous and non᎑porous surfaces is enhanced by elevating absolute humidity Effects of air temperature and relative humidity on coronavirus survival on surfaces Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions Evaluating environmental persistence and disinfection of the Ebola virus Makona variant Ebola virus persistence in the environment: state of the knowledge and research needs Differences in the comparative stability of Ebola virus Makona-C05 and Yambuku-Mayinga in blood Stability of SARS-CoV-2 in different environmental conditions Survival of human coronaviruses 229E and OC43 in suspension and after drying on surfaces: a possible source of hospital-acquired infections Environmental temperature and case fatality of patients with Ebola virus disease in Sierra Leone and Liberia Persistence of the 2009 pandemic influenza A (H1N1) virus on N95 respirators Absolute humidity modulates influenza survival, transmission, and seasonality Role of the air-watersolid interface in bacteriophage sorption experiments Bacteriophage inactivation at the airwater-solid interface in dynamic batch systems Inactivation of some bacterial and animal viruses by exposure to liquid-air interfaces Relationship between humidity and influenza A viability in droplets and implications for influenza's seasonality Mechanical properties of viruses analyzed by atomic force microscopy: a virological perspective Evaluating the environmental persistence and inactivation of MS2 bacteriophage and the presumed Ebola virus surrogate phi6 using low concentration hydrogen peroxide vapor Survival of severe acute respiratory syndrome coronavirus Survival of enteric viruses on environmental fomites The persistence of phi 6 was evaluated as a surrogate for Ebola virus (EBOV) and coronaviruses on porous and nonporous hospital surfaces.


id: cord-303647-c4umbcvn
author: Reed, Patricia E.
title: A New Approach for Monitoring Ebolavirus in Wild Great Apes
date: 2014-09-18
extension: .txt
mime: text/plain
words: 5645
sentence: 199
flesch: 40
cache: cache/cord-303647-c4umbcvn.txt
txt: txt/cord-303647-c4umbcvn.txt
summary:
  This study represents the first time that ebolavirus antibodies have been detected in wild great ape fecal samples, and carries important implications for the future management and survival of these primates. We also tested ape fecal samples obtained from the outbreakfree (NRO) region to explore whether NP antibody detection can be used as a potential surveillance tool.


id: cord-354068-4qlk6y7h
author: Friedrich, Brian M.
title: Potential Vaccines and Post-Exposure Treatments for Filovirus Infections
date: 2012-09-21
extension: .txt
mime: text/plain
words: 10618
sentence: 446
flesch: 39
cache: cache/cord-354068-4qlk6y7h.txt
txt: txt/cord-354068-4qlk6y7h.txt
summary:
  (green monkey disease) Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental ebola virus infections Neutralizing antibody fails to impact the course of ebola virus infection in monkeys Protective efficacy of neutralizing antibodies against ebola virus infection Antibody-dependent enhancement of marburg virus infection Epitopes required for antibody-dependent enhancement of ebola virus infection Antibody-dependent enhancement of ebola virus infection Recombinant human monoclonal antibodies to ebola virus Pre-and postexposure prophylaxis of ebola virus infection in an animal model by passive transfer of a neutralizing human antibody Epitopes involved in antibody-mediated protection from ebola virus Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic fever Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies Enhanced potency of a fucose-free monoclonal antibody being developed as an ebola virus immunoprotectant Characterization of zaire ebolavirus glycoprotein-specific monoclonal antibodies Neutralizing ebolavirus: Structural insights into the envelope glycoprotein and antibodies targeted against it A DNA vaccine for ebola virus is safe and immunogenic in a phase i clinical trial Immune protection of nonhuman primates against ebola virus with single low-dose adenovirus vectors encoding modified gps Development of a preventive vaccine for ebola virus infection in primates A replication defective recombinant ad5 vaccine expressing ebola virus gp is safe and immunogenic in healthy adults Vaccine to confer to nonhuman primates complete protection against multistrain ebola and marburg virus infections Protection of nonhuman primates against two species of ebola virus infection with a single complex adenovirus vector Enhanced protection against ebola virus mediated by an improved adenovirusbased vaccine A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs Recombinant adenovirus serotype 26 (ad26) and ad35 vaccine vectors bypass immunity to ad5 and protect nonhuman primates against ebolavirus challenge Rhabdoviridae: The Viruses and Their Replication Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus Cross-protection against marburg virus strains by using a live, attenuated recombinant vaccine Recombinant vesicular stomatitis virus vector mediates postexposure protection against sudan ebola hemorrhagic fever in nonhuman primates Effective post-exposure treatment of ebola infection Inactivated or liveattenuated bivalent vaccines that confer protection against rabies and ebola viruses Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo Recombinant rna replicons derived from attenuated venezuelan equine encephalitis virus protect guinea pigs and mice from ebola hemorrhagic fever virus Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates Vaccine potential of ebola virus vp24, vp30, vp35, and vp40 proteins Protective cytotoxic t-cell responses induced by venezuelan equine encephalitis virus replicons expressing ebola virus proteins A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose ebola virus challenge Successful topical respiratory tract immunization of primates against ebola virus Parainfluenza viruses Mucosal parainfluenza virus-vectored vaccine against ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of h5n1 highly pathogenic avian influenza virus protect against virus challenge in monkeys Respiratory tract immunization of non-human primates with a newcastle disease virus-vectored vaccine candidate against ebola virus elicits a neutralizing antibody response Ebola virus vp40-induced particle formation and association with the lipid bilayer Contribution of ebola virus glycoprotein, nucleoprotein, and vp24 to budding of vp40 virus-like particles Ebola virus-like particle-based vaccine protects nonhuman primates against lethal ebola virus challenge Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple marburg viruses Filovirus-like particles produced in insect cells: Immunogenicity and protection in rodents Ebola virus vp40-induced particle formation and association with the lipid bilayer Ebola virus vp40 drives the formation of virus-like filamentous particles along with gp Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice Expression and self-assembly of empty virus-like particles of hepatitis e virus Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 l1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems Intranasal immunization with siv virus-like particles (vlps) elicits systemic and mucosal immunity Protection against lethal challenge by ebola virus-like particles produced in insect cells Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies Immunogenicity of the outer domain of a hiv-1 clade c gp120 Increased potency of fc-receptor-targeted antigens Cross-reactive hiv-1-neutralizing activity of serum igg from a rabbit immunized with gp41 fused to igg1 fc: Possible role of the prolonged half-life of the immunogen Ebola virus glycoprotein fc fusion protein confers protection against lethal challenge in vaccinated mice Transgenic plants as protein factories Monoclonal antibody manufacturing in transgenic plants--myths and realities High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system Recombinant pharmaceuticals from plants: The plant endomembrane system as bioreactor Expression of an immunogenic ebola immune complex in nicotiana benthamiana A replicating cytomegalovirus-based vaccine encoding a single ebola virus nucleoprotein ctl epitope confers protection against ebola virus Effector memory t cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge Broadly targeted human cytomegalovirus-specific cd4+ and cd8+ t cells dominate the memory compartments of exposed subjects Human cytomegalovirus tropism for endothelial cells: Not all endothelial cells are created equal Profound early control of highly pathogenic siv by an effector memory t-cell vaccine Chimeric human parainfluenza virus bearing the ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against ebola virus challenge Disseminated intravascular coagulation ( dic) Coli septic shock is prevented by blocking tissue factor with monoclonal antibody Treatment of ebola virus infection with a recombinant inhibitor of factor viia/tissue factor: A study in rhesus monkeys Dose-response study of recombinant factor viia/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor viia complex, in patients undergoing elective coronary angioplasty Marburg virus angola infection of rhesus macaques: Pathogenesis and treatment with recombinant nematode anticoagulant protein c2 Cell penetrating peptide conjugates of steric block oligonucleotides


id: cord-001764-njzyu4mv
author: Hofmann-Winkler, Heike
title: Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976
date: 2015-10-01
extension: .txt
mime: text/plain
words: 4189
sentence: 151
flesch: 42
cache: cache/cord-001764-njzyu4mv.txt
txt: txt/cord-001764-njzyu4mv.txt
summary:
  The viral glycoprotein (GP) facilitates host cell entry and, jointly with cellular interaction partners, constitutes a potential target for antiviral intervention. Here, we show that the GPs of the EBOVs circulating in 1976 and 2014 transduce the same spectrum of target cells, use the same cellular factors for host cell entry, and are comparably susceptible to blockade by antiviral interferon-induced transmembrane proteins and neutralizing antibody KZ52.


id: cord-001542-f089bs8r
author: Lai, Kang Yiu
date: 2014-11-28
extension: .txt
mime: text/plain
words: 11294
sentence: 441
flesch: 36
cache: cache/cord-001542-f089bs8r.txt
txt: txt/cord-001542-f089bs8r.txt
title:
  Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus

summary:
  implications for vaccines and therapies Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily Ebola virus selectively inhibits responses to interferons, but not to interleukin-1beta, in endothelial cells Inflammatory responses in Ebola virus-infected patients Human asymptomatic Ebola infection and strong inflammatory response Infection and activation of monocytes by Marburg and Ebola viruses Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-ICinduced IFN-alpha in vitro Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence Requirements for cell rounding and surface protein down-regulation by Ebola virus glycoprotein Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/ macrophages is a key event Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor Immunopathology of highly virulent pathogens: insights from Ebola virus Ebola haemorrhagic fever Pathogenesis of viral hemorrhagic fever Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection Molecular Basis for Ebola Virus VP35 Suppression of Human Dendritic Cell Maturation Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever The role of antigen-presenting cells in filoviral hemorrhagic fever: gaps in current knowledge Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis Ebola virus does not block apoptotic signaling pathways Characterization of host immune responses in Ebola virus infections Filoviruses and the balance of innate, adaptive, and inflammatory responses Functional CD8+ T cell responses in lethal Ebola virus infection CD8-mediated protection against Ebola virus infection is perforin dependent Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses Correlates of immunity to filovirus infection The Multiple Roles of sGP in Ebola Pathogenesis Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications Infectivity-enhancing antibodies to Ebola virus glycoprotein Antibody-dependent enhancement of Ebola virus infection Epitopes required for antibody-dependent enhancement of Ebola virus infection Ebola virus can be effectively neutralized by antibody produced in natural human infection Structural basis for differential neutralization of ebolaviruses. Ethical considerations for use of unregistered interventions for Ebola viral disease Emerging targets and novel approaches to Ebola virus prophylaxis and treatment World Health Organization: potential Ebola therapies and vaccines Clinical features and pathobiology of Ebolavirus infection Ebola virus: unravelling pathogenesis to combat a deadly disease Delta-peptide is the carboxyterminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis Release of viral glycoproteins during Ebola virus infection The secret life of viral entry glycoproteins: moonlighting in immune evasion The pathogenesis of Ebola hemorrhagic fever Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury Shed GP of Ebola Virus Triggers Immune Activation and Increased Vascular Permeability Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts Ebolavirus Replication and Tetherin/BST-2 The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus A novel mechanism of immune evasion mediated by Ebola virus soluble glycoprotein Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins Ebola virus secretory glycoprotein (sGP) diminishes Fc gamma RIIIB-to-CR3 proximity on neutrophils Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry A new Ebola virus nonstructural glycoprotein expressed through RNA editing Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis The Ebola virus glycoprotein mediates entry via a non-classical dynamindependent


id: cord-296517-414grqif
author: Wong, Gary
title: MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease
date: 2015-10-14
extension: .txt
mime: text/plain
words: 2882
sentence: 104
flesch: 44
cache: cache/cord-296517-414grqif.txt
txt: txt/cord-296517-414grqif.txt
summary:
  A number of recent virus outbreaks have resulted in rapid virus spread, placing demands on the affected health infrastructures and sparking global concern. Emergence of Zaire Ebola virus disease in Guinea Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea Infection with MERS-CoV causes lethal pneumonia in the common marmoset Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak Outbreak of tuberculosis among regular patrons of a neighborhood bar Cynomolgus macaque as an animal model for severe acute respiratory syndrome Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees MERS-COV (97): South Korea, Saudi Arabia.


id: cord-294342-7ycgd0h7
author: Markosyan, Ruben M.
title: Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger
date: 2016-01-05
extension: .txt
mime: text/plain
words: 11770
sentence: 445
flesch: 51
cache: cache/cord-294342-7ycgd0h7.txt
txt: txt/cord-294342-7ycgd0h7.txt
summary:
  This could explain the slow fusion kinetics of EBOV GP mediated fusion, despite classification as a low pH-requiring process. Using the same techniques, we also showed that adding thermolysin to solution did indeed increase cleavage of cell surface GP (Fig 11D) .


id: cord-002676-zwkl1ywk
author: Yu, Dong-Shan
title: The lifecycle of the Ebola virus in host cells
date: 2017-06-15
extension: .txt
mime: text/plain
words: 5334
sentence: 203
flesch: 37
cache: cache/cord-002676-zwkl1ywk.txt
txt: txt/cord-002676-zwkl1ywk.txt
summary:
  How does VP40 associate with the inner leaflet? Ebolavirus comparative genomics Neglected filoviruses The Marburg virus outbreak of 1967 and subsequent episodes A case of Ebola virus infection Clinical illness and outcomes in patients with Ebola in Sierra Leone Ebola virus: from discovery to vaccine Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event Filoviruses and the balance of innate, adaptive, and inflammatory responses How Ebola and Marburg viruses battle the immune system Ebola virus: unravelling pathogenesis to combat a deadly disease Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex Insight into the Ebola virus nucleocapsid assembly mechanism: crystal structure of Ebola virus nucleoprotein core domain at 1.8 A resolution The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3 A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus Membrane binding and bending in Ebola VP40 assembly and egress Oligomerization of Ebola virus VP40 is essential for particle morphogenesis and regulation of viral transcription Processing of the Ebola virus glycoprotein by the proprotein convertase furin Release of viral glycoproteins during Ebola virus infection CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry GP2, from the envelope glycoprotein ectodomain Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function Comparison of N-and O-linked glycosylation patterns of ebolavirus glycoproteins Structure of the Ebola virus glycoprotein spike within the virion envelope at 11 A resolution C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirus Tyrosine kinase receptor Axl enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein Tyro3 family-mediated cell entry of Ebola and Marburg viruses T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus Phosphatidylserine receptors: enhancers of enveloped virus entry and infection The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry Alpha5beta1-integrin controls ebolavirus entry by regulating endosomal cathepsins Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner Cellular entry of ebola virus involves uptake by a macropinocytosislike mechanism and subsequent trafficking through early and late endosomes Ebola virus enters host cells by macropinocytosis and clathrinmediated endocytosis Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses The Roles of Histidines and Charged Residues as Potential Triggers of a Conformational Change in the Fusion Loop of Ebola Virus Glycoprotein Induction of Cell-Cell Fusion by Ebola Virus Glycoprotein: Low pH Is Not a Trigger Ebola sGP-the first viral glycoprotein shown to be C-mannosylated Ebolavirus glycoprotein structure and mechanism of entry Detection of cellcell fusion mediated by Ebola virus glycoproteins Functional importance of the coiled-coil of the Ebola virus glycoprotein Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway Mutational analysis of the putative fusion domain of Ebola virus glycoprotein Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1 Ebola virus entry requires the cholesterol transporter Niemann-Pick C1 Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway Structure of human Niemann-Pick C1 protein VP24 of Marburg virus influences formation of infectious particles Nucleoproteins and nucleocapsids of negative-strand RNA viruses Structural perspective on the formation of ribonucleoprotein complex in negative-sense single-stranded RNA viruses Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism Crystal Structure of the Marburg Virus VP35 Oligomerization Domain Assembly of the Ebola Virus Nucleoprotein from a Chaperoned VP35 Complex An Intrinsically Disordered Peptide from Ebola Virus VP35 Controls Viral RNA Synthesis by Modulating Nucleoprotein-RNA Interactions The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology Ebola virus glycoprotein: proteolytic processing, acylation, cell tropism, and detection of neutralizing antibodies Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling Elucidation of the Cellular Interactome of Ebola Virus Nucleoprotein and Identification of Therapeutic Targets Assembly and budding of Ebolavirus Molecular architecture of the nucleoprotein C-terminal domain from the Ebola and Marburg viruses Multivesicular bodies as a platform for formation of the Marburg virus envelope


id: cord-002013-rb9xdzro
author: Zheng, Xuexing
date: 2016-04-12
extension: .txt
mime: text/plain
words: 6042
sentence: 206
flesch: 47
cache: cache/cord-002013-rb9xdzro.txt
txt: txt/cord-002013-rb9xdzro.txt
title:
  Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection

summary:
  Outbreaks Chronology: Ebola Virus Disease Clinical management of filovirus-infected patients Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo Emergence of Zaire Ebola virus disease in Guinea Ebola Situation Report -16 Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Clinical care of two patients with Ebola virus disease in the United States Two-mAb Cocktail Protects Macaques Against The Makona Variant of Ebola Virus Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Animal models for Ebola and Marburg virus infections Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. Plos neglected tropical diseases 6, e1575 Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates Ebola virus can be effectively neutralized by antibody produced in natural human infection Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies A quantitative immunochemical measure of the primary interaction between I BSA and antibody Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus X.Z., G.W., Y.Z., H.W., S.H., Y.B., X.Q., S.Y. and X.X. performed the experiments and analyzed the results.


id: cord-288029-6l91knu3
author: Elfiky, Abdo A.
title: Ebola virus glycoprotein GP1—host cell-surface HSPA5 binding site prediction
date: 2020-04-14
extension: .txt
mime: text/plain
words: 3101
sentence: 128
flesch: 56
cache: cache/cord-288029-6l91knu3.txt
txt: txt/cord-288029-6l91knu3.txt
summary:
  The C121-C135 region of EBOV GP1 protein that fits well with Pep42 (33.3% identity) is analyzed by the ProtScale web server (ExPASy Bioinformatics Resource Portal) Five identical residues (compared with the Pep42 sequence) were found in the MSA of EBOV GP1 sequences, which are C121, A124, P126, G128, and C135 (the numbering is based on PDB ID: 5JQ3).


id: cord-342052-v4y1xc90
author: Horigan, Verity
date: 2017-10-02
extension: .txt
mime: text/plain
words: 12805
sentence: 392
flesch: 43
cache: cache/cord-342052-v4y1xc90.txt
txt: txt/cord-342052-v4y1xc90.txt
title:
  Application of a quantitative entry assessment model to compare the relative risk of incursion of zoonotic bat-borne viruses into European Union Member States

summary:
  Temporary loss of rabies free Certificate Experimental inoculation of plants and animals with Ebola virus Studies of reservoir hosts for Marburg virus Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections West African Ebola epidemic after one year-slowing but not yet under control Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA Response to imported case of Marburg hemorrhagic fever, the Netherlands Marburg virus infection detected in a common African bat Isolation of genetically diverse Marburg viruses from Egyptian fruit bats Trade control and expert system Pathology of experimental aerosol Zaire Ebolavirus infection in Rhesus macaques Highly pathogenic H5N1 influenza virus in smuggled Thai eagles Stability of Middle East Respiratory syndrome coronavirus in milk Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions A review of epidemiological parameters from Ebola outbreaks to inform early public health decision-making Ebola Hemorrhagic fever associated with novel virus strain Transmission of Ebola virus from pigs to non-human primates Review of Ebola virus infections in domestic animals Case of Marburg haemorrhagic fever imported into the Netherlands from Uganda WHO. Ninth update ECDC, Severe respiratory disease associated with Middle East respiratory syndrome coronavirus (MERS-CoV) 21st update Incubation period of ebola hemorrhagic virus subtype zaire Statistics database Illegal import of bushmeat and other meat products into Switzerland on commercial passenger flights Infection with MERS-CoV causes lethal pneumonia in the common marmoset Trade data Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A Chains of transmission and control of Ebola virus disease in Conakry, Guinea, in 2014: an observational study Hendra virus infection dynamics in Australian fruit bats Lessons from nosocomial viral haemorrhagic fever outbreaks Henipavirus susceptibility to environmental variables European bat lyssaviruses: an emerging zoonosis Ebola hemorrhagic fever transmission and risk factors of contacts Outbreak of Marburg virus disease in Johannesburg Pathogenesis of Ebola hemorrhagic fever in Cynomolgus macaques -evidence that dendritic cells are early and sustained targets of infection Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2 Collection of mammals and arthropods during the epidemic of haemorrhagic fever in Zaire D2R2: an evidencebased decision support tool to aid prioritisation of animal health issues for government funding Natural Hendra virus infection in flying-foxes -tissue tropism and risk factors Person-to-person transmission of Nipah virus in a Bangladeshi community Isolation of Hendra virus from Pteropid bats: a natural reservoir of Hendra virus Pteropid bats are confirmed as the reservoir hosts of Henipaviruses: a comprehensive experimental study of virus transmission Identification of likely natural hosts for equine morbillivirus Hendra virus infection in a veterinarian Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses Demography of straw-colored fruit bats in Ghana Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity Pathogenesis of Marburg hemorrhagic fever in Cynomolgus Macaques On the ecology of the fruit bat, rousettus aegyptiacus leachi (A. Smith, 1829) in the Tsitsikama Coastal National Park Four outbreaks of norovirus gastroenteritis after consuming raspberries The lesions of experimental equine morbillivirus disease in cats and guinea pigs Nipah situation in 2014 Immune and pathophysiological processes in baboons experimentally infected with Ebola virus adapted to guinea pigs Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory Experimental infection of Cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 US epizootic Lethal experimental infections of Rhesus-monkeys by aerosolized Ebola-virus Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya A randomized controlled trial of interventions to impede date palm sap contamination by bats to prevent Nipah virus transmission in Bangladesh Marburg virus Replication, pathogenicity, shedding, and transmission of Zaire Ebolavirus in Pigs Real-time monitoring of cardiovascular function in Rhesus macaques infected with Zaire Ebolavirus Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae Hendra virus and horse owners -risk perception and management Marburg virus in fruit bat Hyspignathus monstrosus Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection Statistical inference in a stochastic epidemic SEIR model with control intervention: Ebola as a case study Fruit bats as reservoirs of Ebola virus Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo Dissemination of Cefotaxime-M-Producing Escherichia coli isolates in poultry farms, but not swine farms, in China Experimental inoculation study indicates swine as a potential host for Hendra virus Foodborne transmission of Nipah virus Proportion of deaths and clinical features in Bundibugyo Ebola virus infection Biosecurity Authority, Ministry of Agriculture and Forestry Is Marburg virus enzootic in Gabon?


id: cord-274377-57zy6unz
author: Long, Jason
date: 2015-02-10
extension: .txt
mime: text/plain
words: 3943
sentence: 154
flesch: 48
cache: cache/cord-274377-57zy6unz.txt
txt: txt/cord-274377-57zy6unz.txt
title:
  Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry

summary:
  In this instance, a 'fusion inhibitor' could target the host cell machinery preventing acidification of the endosome, working to inhibit virus entry of several different viruses. Inhibition of influenza virus entry to cells by means of inhibiting acidification of endosomes has been known for decades 63 , although no current antivirals for influenza have been licensed on this basis.


id: cord-300133-yc2wxgid
author: Martínez, Miguel J.
title: Ebola Virus Infection: Overview and Update on Prevention and Treatment
date: 2015-09-12
extension: .txt
mime: text/plain
words: 4303
sentence: 171
flesch: 42
cache: cache/cord-300133-yc2wxgid.txt
txt: txt/cord-300133-yc2wxgid.txt
summary:
  International Scientific and Technical Committee Large-scale convalescent blood and plasma transfusion therapy for Ebola virus disease Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Emergency evaluation of convalescent plasma for Ebola viral disease (EVD) in Guinea (Ebola-Tx) Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an emprical treatment during outbreaks First Ebola treatment is approved by WHO Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease Antibody-dependent enhancement of Ebola virus infection Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Clinical care of two patients with Ebola virus disease in the United States Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors Putative investigational therapeutics in the treatment of patients with known Ebola infection Accessed 27 Characterization of host immune responses in Ebola virus infections Evasion of the interferon-mediated antiviral response by filoviruses How Ebola virus counters the interferon system Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever Clinical features and pathobiology of Ebolavirus infection Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever ARCA biopharma receives FDA orphan drug designation for rNAPc2 as a potential treatment for Ebola Ebola virus vaccines: an overview of current approaches Evaluation in nonhuman primates of vaccines against Ebola virus Role of VP30 phosphorylation in the Ebola virus replication cycle Perspectives from West Africa Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients Clinical predictors of mortality in patients with Ebola virus disease Clinical features of patients with Ebola virus disease in Sierra Leone Ebola haemorrhagic fever Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure Blood chemistry measurements and D-Dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus Ebola (Ebola virus disease), guidance for collection, transport and submission of specimens for Ebola virus testing World Health Organization.


id: cord-001546-ndz3oarf
author: Ayithan, Natarajan
date: 2015-02-26
extension: .txt
mime: text/plain
words: 5132
sentence: 234
flesch: 47
cache: cache/cord-001546-ndz3oarf.txt
txt: txt/cord-001546-ndz3oarf.txt
title:
  Virus-Like Particles Activate Type I Interferon Pathways to Facilitate Post-Exposure Protection against Ebola Virus Infection

summary:
  Lines of evidence support the critical importance of type I IFN signaling in providing resistance against EBOV infection; mice deficient in Stat1, a transcription factor required for IFN induction, or Ifnar1, encoding the membrane receptor for type I IFNs, are susceptible to wild type Zaire EBOV, against which wild type mice are resistant Mouse-adapted EBOV causes similar acute disease in mice, offering a useful animal model to study EBOV infection


id: cord-001513-p7v5p036
author: Ekins, Sean
title: A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
date: 2014-12-12
extension: .txt
mime: text/plain
words: 4760
sentence: 221
flesch: 53
cache: cache/cord-001513-p7v5p036.txt
txt: txt/cord-001513-p7v5p036.txt
summary:
  Because the original complete sets of FDA approved compounds screened are not publically accessible it is difficult to compare hit rates versus all compounds tested to date. This pharmacophore (with an added van der Waals surface to limit the number of hits retrieved) was then used to screen and score other FDA drugs from score particularly well in terms of docking to VP35.


id: cord-344316-mwnnmwnw
author: Herst, C.V.
date: 2020-04-28
extension: .txt
mime: text/plain
words: 3507
sentence: 129
flesch: 40
cache: cache/cord-344316-mwnnmwnw.txt
txt: txt/cord-344316-mwnnmwnw.txt
title:
  An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design

summary:
  bioinformatics Anti-spike igg causes severe acute lung injury by skewing macrophage responses during acute sars-cov infection T-cell immunity of sars-cov: Implications for vaccine development against mers-cov Flow focusing: a versatile technology to produce size-controlled and specific-morphology microparticles Human ebola virus infection results in substantial immune activation Immunopathogenesis of severe acute respiratory disease in zaire ebolavirus-infected pigs Reliable prediction of t-cell epitopes using neural networks with novel sequence representations Synthetic peptides coupled to the surface of liposomes effectively induce sars coronavirus-specific cytotoxic t lymphocytes and viral clearance in hla-a* 0201 transgenic mice Long-lived memory t lymphocyte responses against sars coronavirus nucleocapsid protein in sarsrecovered patients Hiv control is mediated in part by cd8+ t-cell targeting of specific epitopes Ebola: an analysis of immunity at the molecular level Large scale analysis of peptide -hla-i stability Large scale analysis of peptide -hla-i stability T cell responses to viral infectionsopportunities for peptide vaccination Eliciting cytotoxic t-lymphocyte responses from synthetic vectors containing one or two epitopes in a c57bl/6 mouse model using peptide-containing biodegradable microspheres and adjuvants Conserved peptide vaccine candidates containing multiple ebola nucleoprotein epitopes display interactions with diverse hla molecules Analysis of cd8+ t cell response during the 2013-2016 ebola epidemic in west africa Phase 1 trials of rvsv ebola vaccine in africa and europe Peptide binding to the most frequent hla-a class i alleles measured by quantitative molecular binding assays Measurement of mhc/peptide interactions by gel filtration or monoclonal antibody capture Viral-induced enhanced disease illness Heterosubtypic t-cell immunity to influenza in humans: Challenges for universal t-cell influenza vaccines Cellular immune correlates of protection against symptomatic pandemic influenza The International HIV Controllers Study et al. For HIV and EBOV and influenza in particular, the potential of CTL vaccines has been discussed [21]


id: cord-002185-oz7hras7
author: Nelson, Elizabeth A.
date: 2016-08-02
extension: .txt
mime: text/plain
words: 5079
sentence: 191
flesch: 46
cache: cache/cord-002185-oz7hras7.txt
txt: txt/cord-002185-oz7hras7.txt
title:
  Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications

summary:
  Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease Ebola drugs still stuck in lab Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates Structural and molecular basis for Ebola virus neutralization by protective human antibodies Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak Discovery of an antibody for pan-ebolavirus therapy Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents Development, pharmacology and clinical experience with clomiphene citrate Clomiphene citrate for ovulation induction in women with oligo-amenorrhoea Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents Possible hypothalamic impotencemale counterpart to hypothalamic amenorrhea? Since the two isomers of clomiphene and their hydroxylated metabolites all blocked EBOV VLP entry and replication in cell cultures, the protective effect of clomiphene in the mouse model [20, 21] could have been due to any or all of these forms.


id: cord-002935-jq1xumrh
author: Postnikova, Elena
title: Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs
date: 2018-03-22
extension: .txt
mime: text/plain
words: 6245
sentence: 247
flesch: 51
cache: cache/cord-002935-jq1xumrh.txt
txt: txt/cord-002935-jq1xumrh.txt
summary:
  In contrast, EBOV spread on Vero E6 cells varied considerably between cell passages 6-28 with peak infection (replication efficacy) at cell culture passages 12-14 ( Fig 3A) and equally lower for early or late passages. The EBOV/Mak titer was determined by plaque assay in Vero E6 cells.


id: cord-004335-bw3tziup
author: Perez-Zsolt, Daniel
date: 2019-12-19
extension: .txt
mime: text/plain
words: 7388
sentence: 266
flesch: 32
cache: cache/cord-004335-bw3tziup.txt
txt: txt/cord-004335-bw3tziup.txt
title:
  When Dendritic Cells Go Viral: The Role of Siglec-1 in Host Defense and Dissemination of Enveloped Viruses

summary:
  A mathematical modelling study A case of Ebola virus infection Assessment of the risk of Ebola virus Transmission from bodily fluids and fomites Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts Enhancement of Ebola virus infection by seminal amyloid fibrils Transforming growth factor beta 1 up-regulates CD169 (sialoadhesin) expression on monocytederived dendritic cells: Role in HIV sexual transmission The dendritic cell system and its role in immunogenicity Dendritic cells and the control of immunity Visualizing priming of virus-specific CD8 + T cells by infected dendritic cells in vivo Endogenous MHC class II processing of a viral nuclear antigen after autophagy Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity Dendritic cells in viral pathogenesis: Protective or defective? Anti-immunology: Evasion of the host immune system by bacterial and viral pathogens Dendritic cell functions: Learning from microbial evasion strategies Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4 + T cells Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques The molecule of DC-SIGN captures enterovirus 71 and confers dendritic cell-mediated viral trans-infection Dendritic cells mediate herpes simplex virus infection and transmission through the C-type lectin DC-SIGN Dendritic cells as Achilles' heel and Trojan horse during varicella zoster virus infection Murine cytomegalovirus spreads by dendritic cell recirculation DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes Replication in cells of hematopoietic origin is necessary for Dengue virus dissemination Siglecs and their roles in the immune system HIV-1 capture and transmission by dendritic cells: The role of viral glycolipids and the cellular receptor Siglec-1 CD169-dependent cell-associated HIV-1 transmission: A driver of virus dissemination Anti-Siglec-1 antibodies block Ebola viral uptake and decrease cytoplasmic viral entry Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations Retroviruses human immunodeficiency virus and murine leukemia virus are enriched in phosphoinositides Role of lipids in virus replication Sialyllactose in viral membrane gangliosides is a novel molecular recognition pattern for mature dendritic cell capture of HIV-1 Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses Quantifying lipid contents in enveloped virus particles with plasmonic nanoparticles In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding Siglec regulation of immune cell function in disease Sialic acid binding receptors (siglecs) expressed by macrophages Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus Retroviruses use CD169-mediated trans-infection of permissive lymphocytes to establish infection A protective role for the lectin CD169/Siglec-1 against a pathogenic murine retrovirus Available online The pathogenesis of Ebola virus disease Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169 Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections Microbial translocation is a cause of systemic immune activation in chronic HIV infection The nature of the principal type 1 interferon-producing cells in human blood CD4 + blood dendritic cells are potent producers of IFN-alpha in response to in vitro HIV-1 infection Natural alpha interferon-producing cells respond to human immunodeficiency virus type 1 with alpha interferon production and maturation into dendritic cells Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor Ligands Innate sensing of HIV-infected cells Increased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients Plasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients Plasmacytoid dendritic cells suppress HIV-1 replication but contribute to HIV-1 induced immunopathogenesis in humanized mice Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1 Dendritic cells from the cervical mucosa capture and transfer HIV-1 via Siglec-1 Maturation, activation, and protection of dendritic cells induced by double-stranded RNA Type I interferons produced by dendritic cells promote their phenotypic and functional activation A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells Autocrine type I interferon amplifies dendritic cell responses to lipopolysaccharide via the nuclear factor-κB/p38 pathways Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections Intestinal damage precedes mucosal immune dysfunction in SIV infection Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosides Markedly elevated levels of interferon (IFN)-γ, IFN-α, interleukin (IL)-2, IL-10, and tumor necrosis factor-α associated with fatal Ebola virus infection In vivo Ebola virus infection leads to a strong innate response in circulating immune cells Human asymptomatic Ebola infection and strong inflammatory response Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants Ebola virus-like particles stimulate type


id: cord-293481-bmfj50fb
author: Malin, Jakob J.
title: Remdesivir against COVID-19 and Other Viral Diseases
date: 2020-10-14
extension: .txt
mime: text/plain
words: 9125
sentence: 340
flesch: 37
cache: cache/cord-293481-bmfj50fb.txt
txt: txt/cord-293481-bmfj50fb.txt
summary:
  They found that the activity of remdesivir includes both contemporary human and highly divergent zoonotic CoVs and that natural variations in wild-type RdRp do not confer remdesivir resistance. Recently, the efficacy of remdesivir treatment was finally tested in a rhesus macaque model of SARS-CoV-2 infection (53) .


id: cord-000547-adfigzc1
author: Beniac, Daniel R.
title: The Organisation of Ebola Virus Reveals a Capacity for Extensive, Modular Polyploidy
date: 2012-01-11
extension: .txt
mime: text/plain
words: 7821
sentence: 324
flesch: 47
cache: cache/cord-000547-adfigzc1.txt
txt: txt/cord-000547-adfigzc1.txt
summary:
  (MOV) Physical principles in the construction of regular viruses Studies on the pleomorphism of HVJ virons Infectious bursal disease virus is an icosahedral polyploid dsRNA virus Architecture of ribonucleoprotein complexes in influenza A virus particles Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses Ebola virus: from discovery to vaccine The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor Comprehensive analysis of ebola virus GP1 in viral entry Identification of two amino acid residues on Ebola virus glycoprotein 1 critical for cell entry The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein Functional mapping of the nucleoprotein of Ebola virus Nucleocapsid-like structures of Ebola virus reconstructed using electron tomography Electron tomography reveals the steps in filovirus budding GraFix: stabilization of fragile macromolecular complexes for single particle cryo-EM GraFix: sample preparation for single-particle electron cryomicroscopy Post-crystallization treatments for improving diffraction quality of protein crystals Differentiation of filoviruses by electron microscopy Ebola and Marburg viruses: I. Some ultrastructural differences between strains when grown in Vero cells Ultrastructure of Ebola virus particles in human liver On the etiology of an unknown human infection originating from monkeys Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses Movie S1 3-D reconstruction of Ebola virus nucleocapsid.


id: cord-279152-yh7x7w2q
author: Ndungo, Esther
title: A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles
date: 2016-03-30
extension: .txt
mime: text/plain
words: 5257
sentence: 180
flesch: 42
cache: cache/cord-279152-yh7x7w2q.txt
txt: txt/cord-279152-yh7x7w2q.txt
summary:
  Here, we found that F503¡Y renders cells nonpermissive to EBOV infection because it reduces the apparent binding affinity of GP CL for NPC1 domain C by more than 1,000-fold. The structure rationalizes the effect of these residues on GP-NPC1 binding, as both are located in the ␣4-␣5 loop of NPC1 domain C that directly interacts with EBOV GP CL (loop 2 [26] ) (Fig. 9C) .


id: cord-284845-on97zu6w
author: Falcinelli, Shane D.
date: 2016-07-29
extension: .txt
mime: text/plain
words: 8479
sentence: 321
flesch: 29
cache: cache/cord-284845-on97zu6w.txt
txt: txt/cord-284845-on97zu6w.txt
title:
  Integration of Global Analyses of Host Molecular Responses with Clinical Data To Evaluate Pathogenesis and Advance Therapies for Emerging and Re-emerging Viral Infections

summary:
  The pathway ORA of the kinome data demonstrated that Congo Basin MPXV infection resulted in strong down-regulation of a large proportion of host cell responses, most notably apoptosis, in comparison to West African MPXV. Global suppression of the host antiviral response by Ebolaand Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses Ebola virus modulates transforming growth factor beta signaling and cellular markers of mesenchyme-like transition in hepatocytes Human monkeypox Status of human monkeypox: clinical disease, epidemiology and research A tale of two clades: monkeypox viruses Virulence and pathophysiology of the Congo Basin and West African strains of monkeypox virus in non-human primates Clinical manifestations of human monkeypox influenced by route of infection Cytokine modulation correlates with severity of monkeypox disease in humans Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox Genomic variability of monkeypox virus among humans Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals viral-specific regulation of immune responses Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus Systems kinomics demonstrates Congo Basin monkeypox virus infection selectively modulates host cell signaling responses as compared to West African monkeypox virus Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication Dynamic phosphorylation of VP30 is essential for Ebola virus life cycle Structural phosphoprotein M2-1 of the human respiratory syncytial virus is an RNA binding protein Phosphorylation status of the phosphoprotein P of rinderpest virus modulates transcription and replication of the genome A comparison of the chicken and turkey proteomes and phosphoproteomes in the development of poultry-specific immuno-metabolism kinome peptide arrays Characterization of the host response to pichinde virus infection in the Syrian golden hamster by speciesspecific kinome analysis Computational analysis of the predicted evolutionary conservation of human phosphorylation sites


id: cord-276437-5gkdotvt
author: Liu, William J.
title: Intra-host Ebola viral adaption during human infection
date: 2019-02-20
extension: .txt
mime: text/plain
words: 5118
sentence: 220
flesch: 51
cache: cache/cord-276437-5gkdotvt.txt
txt: txt/cord-276437-5gkdotvt.txt
summary:
  Hematological and biochemical abnormalities were observed in the patients upon hospitalization, which was also reported in the previous studies (Biochemical testing in a laboratory tent and semi-intensive care of Ebola patients on-site in a remote part of Guinea: a paradigm shift based on a bleach-sensitive point-ofcare device. Herein, we have diagnosed a cohort of EBOV patients in Sierra Leone in 2015, during the late phase of the outbreak.


id: cord-002500-9p2n8tjx
author: Lambe, Teresa
date: 2017-05-26
extension: .txt
mime: text/plain
words: 7337
sentence: 228
flesch: 31
cache: cache/cord-002500-9p2n8tjx.txt
txt: txt/cord-002500-9p2n8tjx.txt
title:
  A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?

summary:
  key: cord-002500-9p2n8tjx authors: Lambe, Teresa; Bowyer, Georgina; Ewer, Katie J title: A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? date: 2017-05-26 journal: Philos Trans R Soc Lond B Biol Sci DOI: 10.1098/rstb.2016.0295 sha: doc_id: 2500 cord_uid: 9p2n8tjx Sporadic outbreaks of Ebola virus infection have been documented since the mid-Seventies and viral exposure can lead to lethal haemorrhagic fever with case fatalities as high as 90%. We discuss here the different aspects of the immune assays currently used in the Phase I clinical trials for Ebola virus vaccines, and draw comparisons across the immune outputs where possible; various trials have examined both cellular and humoral immunity in European and African cohorts.


id: cord-289413-mbrw85og
author: Flego, Michela
date: 2019-09-05
extension: .txt
mime: text/plain
words: 5540
sentence: 187
flesch: 41
cache: cache/cord-289413-mbrw85og.txt
txt: txt/cord-289413-mbrw85og.txt
title:
  Intracellular human antibody fragments recognizing the VP35 protein of Zaire Ebola filovirus inhibit the protein activity

summary:
  Ebola haemorrhagic fever Ebola virus disease The discovery of a new Ebolavirus, Bombali virus, adds further support for bats as hosts of Ebolaviruses Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions How Ebola and Marburg viruses battle the immune system Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit The Ebola virus VP35 protein functions as a type I IFN antagonist Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1 Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain Production technologies for monoclonal antibodies and their fragments Expression and targetingof intracellular antibodies in mammalian cells Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein Effects of intrabodies specific for rotavirus NSP5 during the virus replicative cycle Intracellular anti-E7 human antibodies in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells In vivo antitumor effect of an intracellular single-chain antibody fragment against the E7 oncoprotein of human papillomavirus 16 A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models Characterization and binding of intracellular antibody fragments to the hepatitis C virus core protein Generation and characterization of single-chain anti-body fragments specific against transmembrane envelope glycoprotein gp46 of maedivisna virus Isolation of a human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer amyloid-β oligomers Human singledomain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis Purification and functional characterization of the full length recombinant Ebola virus VP35 protein expressed in E. coli dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35 A luciferase reporter gene assay to measure Ebola virus viral protein 35-associated inhibition of double-stranded RNA-stimulated, retinoic acid-inducible gene 1-mediated induction of interferon β Identification of Myricetin as an Ebola virus VP35−doublestranded RNA interaction inhibitor through a novel fluorescence-based assay Design and use of a phage display library. Ebola Virus Diseases New Ebola outbreak declared in Democratic Republic of the Congo Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome Identification of essential outstanding questions for an adequate European laboratory response to ebolavirus ZaireWest Africa Detection of Ebola viral antigen by enzyme-linked immunosorbent assay using a novel monoclonal antibody to nucleoprotein Development, characterization and use of monoclonal VP40-antibodies for the detection of Ebola virus Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus Strategies in Ebola virus disease (EVD) diagnostics at the point of care Antiviral agents against Ebola virus infection: repositioning old drugs and finding novel small molecules Insights into Ebola virus VP35 and VP24 interferon inhibitory functions and their initial exploitation as drug targets, infectious disorders -drug targets A randomized, controlled trial of ZMapp for Ebola virus infection VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study Specific in vivo knockdown of protein function by intrabodies Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism Generation of human single-chain antibody to the CD99 cell surface determinant specifically recognizing Ewing's sarcoma tumor cells Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations


id: cord-004126-u6ts87ur
author: Furuyama, Wakako
date: 2020-01-10
extension: .txt
mime: text/plain
words: 6045
sentence: 235
flesch: 44
cache: cache/cord-004126-u6ts87ur.txt
txt: txt/cord-004126-u6ts87ur.txt
title:
  A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades

summary:
  Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO Novel Eurasian highly pathogenic avian influenza A H5 viruses in wild birds Novel reassortant influenza A(H5N8) viruses among inoculated domestic and wild ducks Intercontinental spread of Asian-origin H5N8 to North America through Beringia by migratory birds Reassortant highly pathogenic influenza A H5N2 virus containing gene segments related to Eurasian H5N8 in British Columbia Novel reassortant highly pathogenic H5N6 avian influenza viruses in poultry in China Characterization of three H5N5 and one H5N8 highly pathogenic avian influenza viruses in China Avian flu: isolation of drug-resistant H5N1 virus Lethal H5N1 influenza viruses escape host anti-viral cytokine responses Scientific barriers to developing vaccines against avian influenza viruses Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture Emerging vaccines for influenza Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants A VSV-based Zika virus vaccine protects mice from lethal challenge Single-dose liveattenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials Ebola: lessons on vaccine development Keeping your cool -doing Ebola research during an emergency Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection Characterization of a bivalent vaccine capable of inducing protection against both Ebola and cross-clade H5N1 influenza in mice Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus A single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1 Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: abridged chronology and virus isolation H5N1 highly pathogenic avian influenza: timeline of major events Brief literature review for the WHO global influenza research agenda-highly pathogenic avian influenza H5N1 risk in humans Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge Toward a unified nomenclature system for highly pathogenic avian influenza virus (H5N1) Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness Haemagglutination-inhibiting antibody to influenza virus Cross-clade immunity in cats vaccinated with a canarypoxvectored avian influenza vaccine Towards a universal influenza vaccine: different approaches for one goal Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates Ebola haemorrhagic fever VSVDeltaG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection Cell culture-based influenza vaccines: a necessary and indispensable investment for the future Ebola vaccines in clinical trial: the promising candidates Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses We thank the animal care staff of the Rocky Mountain Veterinary Branch (NIAID, NIH) for their support of the animal experiments. Next, we performed a series of studies measuring the rate and extent of vaccine virus growth over time.


id: cord-011129-btaxvmsr
author: Di Paola, Nicholas
title: Viral genomics in Ebola virus research
date: 2020-05-04
extension: .txt
mime: text/plain
words: 9445
sentence: 304
flesch: 28
cache: cache/cord-011129-btaxvmsr.txt
txt: txt/cord-011129-btaxvmsr.txt
summary:
  identification of transmission routes using pathogen deep-sequence data The pathogenesis of Ebola virus disease Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus Characterization of host immune responses in Ebola virus infections Tissue-based class control: the other side of tolerance Uveal involvement in Marburg virus disease Spermatogene Übertragung des Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo Marburg-virus disease in Kenya Ebola virus transmission caused by persistently infected survivors of the 2014-2016 outbreak in West Africa Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors Ebola virus persistence in semen of male survivors Active Ebola virus replication and heterogeneous evolutionary rates in EVD survivors Post-Ebola syndrome Sequelae of Ebola virus disease: the emergency within the emergency Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys Ebola virus disease complicated by late-onset encephalitis and polyarthritis Late Ebola virus relapse causing meningoencephalitis: a case report An update on ocular complications of Ebola virus disease Persistence of Ebola virus in ocular fluid during convalescence Ocular immune privilege and transplantation Ebola RNA persistence in semen of Ebola virus disease survivors -final report Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo A longitudinal study of Ebola sequelae in Liberia Persistence and sexual transmission of filoviruses Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses Persistent Marburg virus infection in the testes of nonhuman primate survivors A case of human Lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses Possible sexual transmission of Crimean-Congo hemorrhagic fever Lassa fever: epidemiology, clinical features, and social consequences Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report Persistent infection with Ebola virus under conditions of partial immunity Ebola virus persistence in breast milk after no reported illness: a likely source of virus transmission from mother to child Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa virus exposure in cynomolgus macaques Persistence of Lassa virus associated with severe systemic arteritis in convalescing guinea pigs (Cavia porcellus) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study Asymptomatic infection and unrecognised Ebola virus disease in Ebola-affected households in Sierra Leone: a cross-sectional study using a new non-invasive assay for antibodies to Ebola virus Human asymptomatic Ebola infection and strong inflammatory response Risk factors associated with Ebola and Marburg viruses seroprevalence in blood donors in the Republic of Congo Risk factors for Zaire ebolavirusspecific IgG in rural Gabonese populations Unique human immune signature of Ebola virus disease in Guinea Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity Use of reverse genetics to inform Ebola outbreak responses Therapeutic strategies to target the Ebola virus life cycle Effects of life history and ecology on virus evolutionary potential Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms Immune parameters correlate with protection against Ebola virus infection in rodents and nonhuman primates Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) Here, we describe how genomics has been historically used to investigate Ebola virus disease outbreaks and how new technologies allow for rapid, large-scale data generation at the point of care.


id: cord-000804-0hlj6r10
author: Brauburger, Kristina
title: Forty-Five Years of Marburg Virus Research
date: 2012-10-01
extension: .txt
mime: text/plain
words: 14933
sentence: 638
flesch: 42
cache: cache/cord-000804-0hlj6r10.txt
txt: txt/cord-000804-0hlj6r10.txt
summary:
  Cell Host Microbe Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin The GP-protein of Marburg virus contains the region similar to the 'immunosuppressive domain' of oncogenic retrovirus P15E proteins Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses Ectodomain shedding of the glycoprotein GP of Ebola virus Sorting of Marburg virus surface protein and virus release take place at opposite surfaces of infected polarized epithelial cells Interactions with the host cell Tsg101 is recruited by a late domain of the nucleocapsid protein to support budding of Marburg virus-like particles Phosphorylation of Marburg virus matrix protein VP40 triggers assembly of nucleocapsids with the viral envelope at the plasma membrane Establishment and application of an infectious virus-like particle system for Marburg virus VP40, the matrix protein of Marburg virus, is associated with membranes of the late endosomal compartment Interactions of Marburg virus nucleocapsid proteins The matrix protein of Marburg virus is transported to the plasma membrane along cellular membranes: exploiting the retrograde late endosomal pathway Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein Multivesicular bodies as a platform for formation of the Marburg virus envelope Vacuolar protein sorting pathway contributes to the release of Marburg virus Oligomerization and polymerization of the filovirus matrix protein VP40 Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in Viruses 2012, 4 1917 the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP Regulation of Marburg virus (MARV) budding by Nedd4.1: a different WW domain of Nedd4.1 is critical for binding to MARV and Ebola virus VP40 Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding Marburg Virus VP40 Antagonizes Interferon Signaling in a Species-Specific Manner Marburg virus evades interferon responses by a mechanism distinct from ebola virus Global suppression of the host antiviral response by Ebolaand Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold Filoviral immune evasion mechanisms Development and characterization of a mouse model for Marburg hemorrhagic fever Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process VP24 of Marburg virus influences formation of infectious particles Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly Three of the four nucleocapsid proteins of Marburg virus, NP, VP35, and L, are sufficient to mediate replication and transcription of Marburg virus-specific monocistronic minigenomes Ultrastructural organization of recombinant Marburg virus nucleoprotein: comparison with Marburg virus inclusions Morphology of Marburg virus NP-RNA Nucleocapsid formation and RNA synthesis of Marburg virus is dependent on two coiled coil motifs in the nucleoprotein Characterization of filovirus protein-protein interactions in mammalian cells using bimolecular complementation Genus-specific recruitment of filovirus ribonucleoprotein complexes into budding particles The nucleoprotein of Marburg virus is phosphorylated The nucleoprotein of Marburg virus is target for multiple cellular kinases Phosphorylation of Marburg virus NP region II modulates viral RNA synthesis Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription Co-and posttranslational modifications and functions of Marburg virus proteins Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus Phosphorylation of VP30 Impairs Ebola Virus transcription Phosphorylation of Marburg virus VP30 at serines 40 and 42 is critical for its interaction with NP inclusions Ebola virus transcription activator VP30 is a zinc-binding protein Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association The Ebola Virus VP30 is an RNA Binding Protein The Ebola virus ribonucleoprotein complex: a novel VP30-L interaction identified Ebola Virus VP30-Mediated Transcription Is Regulated by RNA Secondary Structure Formation Role of Ebola virus VP30 in transcription reinitiation Role of VP30 phosphorylation in the Ebola virus replication cycle Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30 Inhibition of Marburg virus protein expression and viral release by RNA interference Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains Characterization of the receptor-binding domain of Ebola glycoprotein in viral entry Comprehensive analysis of ebola virus GP1 in viral entry Structural basis for membrane fusion by enveloped viruses Covalent modifications of the ebola virus glycoprotein LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus The DC-SIGN-related lectin LSECtin mediates antigen capture and pathogen binding by human myeloid cells Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha Association of the caveola vesicular system with cellular entry by filoviruses Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection Differential requirements for clathrin endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal acidification, structural integrity, and cathepsin (B and L) activity Ebola virus enters host cells by macropinocytosis and clathrinmediated endocytosis VP24 inhibits transcription and replication of the EBOV genome Ebola virus matrix protein VP40 uses the COPII transport system for its intracellular transport Budding of Marburgvirus is associated with filopodia Electron tomography reveals the steps in filovirus budding Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread Basolateral budding of Marburg virus: VP40 retargets viral glycoprotein GP to the basolateral surface Marburg virus and mononuclear phagocytes: study of interactions) Cellular immune response to Marburg virus infection in cynomolgus macaques Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques Development of a model for marburgvirus based on severe-combined immunodeficiency mice Ebola virus infection in guinea pigs: Presumable role of granulomatous inflammation in pathogenesis Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy Filovirusinduced endothelial leakage triggered by infected monocytes/macrophages Breakdown of paraendothelial barrier function during Marburg virus infection is associated with early tyrosine phosphorylation of platelet endothelial cell adhesion molecule-1 Infection and activation of monocytes by Marburg and Ebola viruses Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses


